Glaucoma Press Releases

Over the past twelve months there has been significant advancements in cell gene therapy for inherited retinal dystrophy, with an FDA approval of Spark Therapeutics' Voretigene – the first gene therapy approved in ophthalmology.

Specialty Eye Institute will host a 40th Anniversary Celebration on Wednesday, July 18th from 5:30 p.m. – 7:30 p.m. The event will be held at Specialty Eye Institute's Jackson office at 1116 W. Ganson Ave., Jackson, MI 49202, where it all began.

Glaucoma Therapeutics Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026